Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Neuroblastoma 1Graft vs Host Disease 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 14Temozolomide 10Magnetic Resonance Spectroscopy 10dinutuximab 9Biopsy 9X-Rays 8Specimen Handling 8Irinotecan 8Phantoms, Imaging 7fludarabine 6Topotecan 6Nuclear Medicine Department, Hospital 6Vincristine 53-Iodobenzylguanidine 5sargramostim 4fludarabine phosphate 4Melphalan 4Isotretinoin 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3Radiotherapy 3Filgrastim 3Doxorubicin 3Colony-Stimulating Factors 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Hematopoietic Stem Cell Transplantation × 90 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡